Home › Funds › Baron Health Care Fund
Fund family: BARON SELECT FUNDS · Filed by BARON SELECT FUNDS (CIK 1217673) · SEC series S000061847
Share classes and tickers: BHCFX (C000200239), BHCHX (C000200240), BHCUX (C000200241)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 447 with, 14 against, 0 abstentions (not counted as with management). Shareholder proposals: 2 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.
Each ballot item this fund voted is set against the votes of the other BARON SELECT FUNDS funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BARON SELECT FUNDS funds on 3 items (30.0% of the 10 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BARON SELECT FUNDS funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 2026-05-04 | Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. | Against | FOR — 3 of 3 BARON SELECT FUNDS funds | For | Not approved, 33.7% support |
| Eli Lilly and Company | 2026-05-04 | Shareholder Shareholder proposal to prepare an annual lobbying report. | Against | FOR — 3 of 3 BARON SELECT FUNDS funds | For | Not approved, 14.9% support |
| Eli Lilly and Company | 2026-05-04 | Election of the following directors, each to serve a three-year term: William Kaelin, Jr. | For | AGAINST — 3 of 3 BARON SELECT FUNDS funds | For | Elected, 95.1% support |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 81.1% of this fund’s 461 such votes could be given a sector; the other 87 (18.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 321 | 14 | 4.4% |
| Industrials | 38 | 0 | 0.0% |
| Real Estate | 11 | 0 | 0.0% |
| Technology | 4 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 282 | 0 |
| Audit-related | 47 | 0 |
| Say-on-Pay | 44 | 0 |
| Compensation | 29 | 0 |
| Capital Structure | 27 | 0 |
| Corporate Governance | 27 | 8 |
| Other Social Issues | 4 | 3 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $19M | 10 | 2 |
| argenx SE | November 18, 2025 | $12M | 1 | 0 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $7M | 13 | 0 |
| McKesson Corporation | July 30, 2025 | $7M | 14 | 0 |
| Mettler-Toledo International Inc. | May 7, 2026 | $7M | 11 | 0 |
| Johnson & Johnson | April 23, 2026 | $6M | 15 | 1 |
| Teva Pharmaceutical Industries Limited | May 28, 2026 | $6M | 3 | 0 |
| argenx SE | May 6, 2026 | $5M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 12, 2026 | IDEXX Laboratories, Inc. | Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 4, 2026 | West Pharmaceutical Services, Inc. | Shareholder proposal regarding an independent Board Chair policy. Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | For | Against |
465 ballot items at 47 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Baron Health Care Fund (BHCFX) voted at 47 shareholder meetings of 46 companies, on 465 ballot items in all. Where management made a recommendation, the fund followed it on 97.0% of the items and voted against it 14 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 14 shareholder proposals. It voted differently from most BARON SELECT FUNDS funds on 3 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.